Becton, Dickinson & Co. diskutieren

Becton, Dickinson Comp.

Becton, Dickinson Comp. sollte demnächst wieder an die 60er Marke heranlaufen können.                                                   

Interesant

Guter Wert im Medizin bzw Gesundheitssektor der aus meiner Sicht noch interesant werden wird. Mal schauen ob ich recht behalten werde.

BECTON DICKINSON

 ./..

Kennt nur eine Richtung

Sehr  tolle Medinzintechnik Aktie die kurzfristig ein Hold ist, aber langfristig ein Buy!

Stock analysts at Deutsche Bank raised their price objective on shares of Becton, Dickinson and (NYSE:BDX) from $141.00 to $145.00 in a report issued on Wednesday. The firm currently has a “hold” rating on the stock. Deutsche Bank’s price objective points to a potential upside of 7.62% from the company’s current price.

Shares of Becton, Dickinson and (NYSE:BDX) traded up 4.55% on Wednesday, hitting $140.86. 1,134,341 shares of the company’s stock traded hands. Becton, Dickinson and has a 1-year low of $104.94 and a 1-year high of $135.27. The stock’s 50-day moving average is $127.3 and its 200-day moving average is $119.8. The company has a market cap of $27.022 billion and a P/E ratio of 22.49.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.66 by $0.02. The company had revenue of $2.20 billion for the quarter, compared to the consensus estimate of $2.16 billion. During the same quarter in the prior year, the company posted $1.54 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. On average, analysts predict that Becton, Dickinson and will post $6.80 earnings per share for the current fiscal year. 

The company also recently announced a quarterly dividend, which is scheduled for Wednesday, December 31st. Investors of record on Wednesday, December 10th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 1.78%. 

A number of other analysts have also recently weighed in on BDX. Analysts at JPMorgan Chase & Co. upgraded shares of Becton, Dickinson and from a “neutral” rating to an “overweight” rating in a research note on Wednesday. They now have a $160.00 price target on the stock, up previously from $134.00. Separately, analysts at Evercore ISI reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Tuesday. They now have a $130.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Becton, Dickinson and in a research note on Wednesday, November 5th. They now have a $133.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $126.64.

Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Dividendenaristokrat

Der Medizintechniker Becton, Dickinson and Company (ISIN: US0758871091, NYSE: BDX) wird eine Quartalsdividende von 66 US-Cents ausschütten. Damit erhalten die Aktionäre auf das Gesamtjahr gerechnet weiterhin 2,64 US-Dollar. Die derzeitige Dividendenrendite liegt beim aktuellen Börsenkurs von 175,03 US-Dollar (Stand: 26. Juli 2016) bei 1,51 Prozent. Ausgeschüttet wird die Dividende am 30. September 2016 (Record day: 9. September 2016).

BD steigerte seine vierteljährliche Dividende im November 2015 um zehn Prozent oder sechs US-Cents auf den aktuellen Betrag. Mit dieser Steigerung hatte der Konzern die Dividende das 44. Jahr in ununterbrochener Folge erhöht. Damit zählt Becton Dickinson zu den Dividendenaristokraten – das sind Unternehmen, die seit mindestens 25 Jahren die Dividende jedes Jahr erhöhen.

Becton Dickinson and Company ist ein amerikanisches Medizintechnik-Unternehmen. Das Unternehmen wurde 1897 gegründet und hat seinen Firmensitz in Franklin Lakes im US-Bundesstaat New Jersey. Zu den Produkten zählen medizinische Einmalartikel, Gerätesysteme und Reagenzien. Im Fiskaljahr 2015 wurde ein Umsatz von 10,3 Mrd. US-Dollar bei einem operativen Gewinn von 1,1 Mrd. US-Dollar erwirtschaftet. Es werden 45.000 Mitarbeiter beschäftigt.

Redaktion MyDividends.de

The

Trend is your friend.